Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Page 2

Apic Bio picks up $40m
The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.
Sanofi hands $91m to Biontech
Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.
Sophia Genetics generates $77m
The genomic testing platform developer has now raised some $140m, eight years after being co-founded in EPFL's Innovation Park by researchers from EMBL, Stanford and Geneva University.
Cabaletta Bio captures $50m
Autoimmune disease therapy spinout Cabaletta Bio's series B round brought its total to at least $88m allowed the university to pare back its shareholding.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Boosted hitches $60m series B ride
Stanford-StartX Fund has returned to pump funding into electric skateboard manufacturer Boosted, helping to take the company’s total funding to $70m.
Stanford's Annexon annexes $75m
Immunotherapy spinout Annexon Biosciences collected funding from Novartis Venture Fund in a series C round that brought its total funding to $154m.
Entrada darts to $59m series A round
MRL Ventures Fund and Roche Fund have taken part in the intracellular drug developer's series A, which is commercialising research by Prof Dehua Pei at OSU.
Synspective receives $2.7m boost
Synspective has been backed by a University of Tokyo VC vehicle in its bid to launch a constellation of 25 small Earth observation satellites powered by synthetic aperture radar.
Genomics encounters $42m series B
Foresite Capital and F-Prime Capital joined earlier series B investors including Oxford Science Innovations to take Oxford drug discovery spinout Genomics’ total funding to $58.2m.

test reg

Login